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Background: In patients suspected of new slow-onset heart failure, data on the comparative diagnostic
performance of automated B-type natriuretic peptide (BNP) assays are scarce.
Methods and Results: Twohundred patients referred to a heart failure outpatient diagnostic facility underwent
standarddiagnosticwork-up includingechocardiography.The reference standard for thediagnosis of heart failure
was an expert panel conclusion.N-terminal pro-BNPonElecsys andBNPonAxsymandCentaurmachineswere
measured in a single batch. Datawere available for 172 patients; 51 had heart failure (29.7%).All 3 tests had high
c-statistic values. An intermediate-risk subset of 111 patients (34%with heart failure) was created by excluding
patients with very high or very low probability based on history and physical examination, the subgroup most in
need of an additional test. Applying different thresholds for ruling heart failure in or out, the positive predicted
values in this ‘‘gray zone’’ groupwere 75%, 76%, and 72%, respectively, and the negative predictive values 83%,
71%, and 85%, with the remaining 50% of patients havingw18% probability of heart failure.
Conclusion: In practice, a valid diagnosis in patients suspected of slow-onset heart failure remains
elusive for many in the absence of echocardiographic imaging. (J Cardiac Fail 2011;17:729e734)
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They are particularly useful in settings with limited ac-
cess to other diagnostic tests, such as echocardiography,
notably in primary care. BNP and the biologically inac-
tive N-terminal counterpart (NT-proBNP) peptide assays
are readily available with fully automated immunoassay
as well as point-of-care testing methods.
Data on the comparative performance of 3 popular au-
tomated assays in patients suspected of new slow-onset
heart failure are lacking. Our aim was to assess the com-
parative diagnostic accuracy and utility of NT-proBNP
measured with the Roche assay, BNP measured with the
Abbott assay, and BNP with the Bayer assay in patients
suspected of new slow-onset heart failure in primary
care on top of the preceding tests (signs and symptoms,
history, physical examination).2 We were particularly in-
terested, as a measure of utility, in the predicted values
of the 3 BNP tests in those patients where the clinical pic-
ture is unclear.
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Patient Population
The first 200 patients included in a larger study, the Utrecht Heart
Failure OrganisationeInitial Assessment (UHFO-IA),3 had their
blood drawn for assessment of BNP by the 3 assays. The UHFO-
IA recruited patients suspected of heart failure by their general prac-
titioner (GP). The only exclusion criteria were a previous diagnosis
of heart failure or acute signs and symptoms demanding immediate
treatment. The objective was to include patients where the GP could
neither immediately and safely rule out nor diagnose heart failure,
ie, patients in need of additional diagnostic work-up. Patients were
referred to rapid access heart failure outpatient diagnostic facilities
available in 8 hospitals. All patients underwent standard diagnostic
work-up including electrocardiogram (ECG), laboratory measure-
ments, chest x-ray, spirometry, and echocardiography. The refer-
ence (‘‘gold’’) standard for the diagnosis of heart failure was the
decision of an expert panel consisting of a cardiologist, a pulmonol-
ogist, and a GP. The panel based their decision on the results of all
diagnostic tests: medical history, anamnesis, physical examination,
laboratory values, ECG, spirometry, chest x-ray, echocardiography,
and 6 months of clinical follow-up data (eg, to monitor the effect of
targeted therapy). The panel did not receive the BNP results, to
prevent incorporation bias, because one of the aims of the original
study was to assess the added diagnostic value of BNP in these
patients. The final decision of the panel was made following the
criteria for heart failure of the 2008 ESC guideline1 and more
recently explicitly for patients suspected of heart failure by the
Heart Failure Society of America 2010 heart failure guideline.4
This study was approved by the Medical Ethical Committee of
the St Antonius Hospital, Nieuwegein, The Netherlands.
B-Type Natriuretic Peptide Measurements
Blood samples were taken and specimens of plasma were stored
at 70C. At the end of the study, NT-proBNP and BNP levels
were measured for all patients in a single batch after the frozen
specimens were thawed at the Saltro laboratories in Utrecht,
The Netherlands. NT-proBNP was measured with an automated
noncompetitive immunoradiometric assay (Roche, Mannheim,
Germany) on an Elecsys 1010 analyzer. For plasma BNP measure-
ments, the automated Abbott Axsym BNP immunoassay (Abbott,
Park, Illinois, USA) and Advia Centaur BNP immunoassay
(Siemens Healthcare Diagnostics, Deerfield, Illinois, USA) were
used. Total coefficients of variation are reported to be 4.4%,
5.5% and 0.8%, respectively.5 Results are given in pg/mL.
Data Analysis
The ability of aBNPassay diagnostic test to discriminate between
patients with and without heart failure was assessed bymeans of the
c-statistic (area under the receiver operating characteristic curve).
The c-statistic is a rank order measure of discrimination combining
sensitivity and specificity; specifically, the c-statistic represents the
probability of a random patient with heart failure having a higher
value of plasma BNP compared with a random patient without heart
failure.6 To assess the calibration we performed a goodness-of-fit
test, the Hosmerele Cessie (HLC) test,7 in which a smaller P value
indicates larger difference between observed and expected probabil-
ities of heart failure. Additionally, we computed predicted values,
taking the 25th and 75th percentiles of BNP values to respectively
‘‘rule out’’ and ‘‘rule in’’ heart failure as an arbitrary example to en-
able comparison of the 3 BNP assays. In daily practice, the cutoffsruling out and diagnosing heart failure are chosen by the physician,
taking into account the individual patient for whom the decision has
to be made.
One other algorithm we assessed was published by the ESC
in its 2008 guideline: Heart failure is unlikely when BNP !100
pg/mL (NT-proBNP!400 pg/mL), whereas heart failure is likely
when BNP O400 pg/mL (NT-proBNP O2,000 pg/mL).1
To gain more insight into the utility of the 3 tests, we selected
those patients for whom the test would be considered to be most ap-
propriately indicated, ie, as additional diagnostic test in patients
where there is still diagnostic uncertainty after history taking and
physical examination. To that end, we computed the predicted prob-
ability of heart failure for all patients based on a multivariate logis-
tic regression model and selected the group of patients with!80%
probability and O10% probability. The multivariate model used
age, history of myocardial infarction, coronary artery bypass graft
or percutaneous coronary intervention, use of a loop diuretic, dis-
placed ictus cordis, lung crackles, irregular pulse, pulse rate, heart
murmur suggestive of mitral regurgitation, and elevated jugular ve-
nous pressure to predict the presence of heart failure. This model
was derived from all of the 721 patients from the main study, where
the analyses took the natural hierarchy according to daily practice
(starting with easily obtainable items from history taking) into
account. Variables were allowed in the model only if they had ad-
ditional value (based on the likelihood ratio test) to items already
included in the model.3 More than 80% probability of heart failure
present after history taking and physical examination would consti-
tute the arbitrary threshold of not needing additional diagnostic
tests, and vice versa,!10% is the arbitrary threshold of not needing
additional diagnostic tests because heart failure is discarded from
the differential diagnosis. In the 10%e80% probability of heart fail-
ure group, we computed the predicted values of the 3 BNP tests.
All statistical calculations were performed with R, version 2.10
(http://www.r-project.org/).Results
Of the 200 samples, 28 were lost due to technical or orga-
nizational reasons, eg, insufficient amount of blood, ID label
unreadable, or lost. There were no relevant differences be-
tween patients with and without plasma samples (data not
shown); consequently, all analyses were performed on 172
patients. The mean age of the 172 patients was 70.2 years
and 66% were female (Table 1). Heart failure was diagnosed
by the panel in 51 patients (29.7%), of whom 41% had an
ejection fraction as estimated by echocardiography of
$45%e50%. All patients had $1 complaints compatible
with heart failure. Physical examination signs compatible
with heart failure were more common among patients with
heart failure. In Table 2 and Figure 1 the uni- and bivariate
measures of the 3 BNP tests are presented. As expected,
the distribution off all BNP assays was skewed to the right;
therefore, we used the log-transformed values in all compu-
tations. The Pearson correlation coefficient on the log scale
was lowest for NT-proBNP with BNP on Axsym (0.84)
and highest for NT-proBNP with BNP on Centaur (0.90).
The largest c-statistic, the measure of discriminating
ability between heart failure present versus heart failure ab-
sent, was found for the NT-proBNP test (0.86), but no
Table 1. Characteristics of Patients Suspected of Heart Failure (HF) and According to the Presence or Absence of HF
All Participants
(n 5 172)
HF Present
(n 5 51)
HF Absent
(n 5 121)
Intermediate Probability
of HF (n 5 111; 38 HF)
n % n % n % n %
Age, y, mean (SD) 70.2 (11.3) 75.4 (9.7) 68 (11.2) 74.4 (8.3)
Female 113 65.7 30 58.8 83 68.6 71 64.0
Complaints
Shortness of breath 103 59.9 41 80.4 62 51.2 76 68.5
Fatigue 121 70.3 40 78.4 81 66.9 79 71.2
Ankle swelling 83 48.3 31 60.8 52 43.0 54 48.6
Orthopnoea or paroxysmal nocturnal dyspnoea 58 33.7 23 45.1 35 28.9 35 31.5
History
Never smoked 67 39.0 17 33.3 50 41.3 48 43.2
Hypertension 88 51.2 28 54.9 60 49.6 62 55.9
Diabetes 29 16.9 13 25.5 16 13.2 25 22.5
Stroke or TIA 15 8.7 9 17.6 6 5.0 11 9.9
Atrial fibrillation 8 4.7 3 5.9 5 4.1 8 7.2
MI, PCI, or CABG 9 5.2 7 13.7 2 1.7 7 6.3
COPD 47 27.3 16 31.4 31 25.6 33 29.7
Medication
ACEI or AT2 blocker 52 30.2 22 43.1 30 24.9 40 36.0
Loop diuretic 61 35.5 32 62.7 29 24.0 49 44.1
b-Blocker 49 28.5 15 29.4 34 28.1 30 27.0
Physical examination and other test results
BMI, kg/m2, mean (SD) 29.5 (5.4) 28.5 (5.1) 29.9 (5.4) 28.9 (5.3)
Pulmonary rales 26 15.1 14 27.5 12 9.9 19 17.1
Elevated jugular venous pressure 15 8.7 11 21.6 4 3.3 9 8.1
Laterally displaced apex beat 16 9.3 14 27.5 2 1.7 8 7.2
Peripheral edema 48 27.9 20 39.2 28 23.1 31 27.9
eGFR, mL/min/m2, mean (SD) 62.9 (15.0) 58.6 (15.4) 64.8 (14.4) 62 (14.6)
Ejection fraction O0.45e0.50 on echocardiogram 130 75.6 20 39.2 110 90.1 81 73.0
TIA, transient ischemic attack; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; COPD, chronic
obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitor; AT2, angiotensin II; BMI, body mass index; eGFR, estimated glomerular
filtration rate by the Modification of Diet in Renal Disease formula.
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of the tests (Table 2).
For the utility of the 3 tests, we selected the patients of
intermediate risk of heart failure after history taking andTable 2. Univariate Measures and Diagnostic Accuracy o
(n 5 172; Prevalence of H
N
All patients
Geometric mean
Median (25th75th percentile) 16
Patients with heart failure
Geometric mean
Median (25th75th percentile) 185
Patients without heart failure
Geometric mean
Median (25th75th percentile) 12
c-Statistic (95% CI) 0.86
HLC P value for calibration
PPV O 75th percentile (95% CI) 0.81
NPV ! 25th percentile (95% CI) 0.89
PPV BNP O400 pg/mL, NT-proBNP O2,000 pg/mL (n)
NPV BNP !100 pg/mL, NT-proBNP !400 pg/m (95% CI) 0.76
Applied in 111 patients at intermediate risk of heart failure and 34.2% prevalen
c-Statistic (95% CI) 0.86
PPV O 75th percentile (95% CI) 0.75
NPV ! 25th percentile (95% CI) 0.83
PPV BNP O400 pg/mL, NT-proBNP O2,000 pg/mL (n) na
NPV BNP !100 pg/mL, NT-proBNP !400 pg/m (95% CI) 0.71
BNP, B-type natriuretic peptide; NT-proBNP, N-terminal proeB-type natriure
mean; c-statistic, area under the receiver operating characteristic curve, a measu
0.5 equivalent to flipping a coin; CI 5 confidence interval; PPV, positive predicphysical examination (O10% and !80%). This subset
contained 111 patients, of whom 38 (34.2%) had heart fail-
ure; the characteristics are presented in Table 1. Application
of the 3 BNP tests in these patients resulted in loss off 3 BNP Assays for the Diagnosis of Heart Failure
eart Failure 29.7%)
T-proBNP Axsym-BNP Centaur-BNP
24.8 18 13.2
(7e55) 14 (8e34) 10 (5e26)
129.5 61.3 50.4
(28e470) 85 (26e288) 58 (18e222)
12.4 10.7 7.5
(6e22) 12 (6e18) 7 (4e14)
(0.80e0.92) 0.82 (0.73e0.90) 0.83 (0.76e0.91)
.051 !.001 .005
(0.67e0.92) 0.74 (0.59e0.86) 0.77 (0.61e0.88)
(0.75e0.97) 0.84 (0.69e0.93) 0.88 (0.75e0.96)
1/1 5/5 3/3
(0.69e0.82) 0.81 (0.73e0.87) 0.80 (0.73e0.86)
ce
(0.73e0.89) 0.79 (0.68e0.90) 0.81 (0.71e0.91)
(0.57e0.89) 0.76 (0.56e0.90) 0.72 (0.53e0.86)
(0.59e0.96) 0.71 (0.48e0.89) 0.85 (0.62e0.97)
(N 5 0) 3/3 2/2
(0.61e0.79) 0.76 (0.66e0.84) 0.76 (0.66e84)
tic peptide; geometric mean, exponential of the mean of log-transformed
re of discrimination, with a value of 1 representing perfect discrimination,
ted value; NPV, negative predicted value.
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Fig. 1. Kernel density plot (violin plot) plus boxplot for patients with and without heart failure (HF) on a log scale. Top left: NT-proBNP;
top right: BNP on Axsym; bottom left: BNP on Centaur.
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relevant changes between the tests (Table 2). The number
of patients associated with application of the ‘‘percentile’’
rule-in and rule-out cutoff levels is presented in Table 3.
At best, the prior probability of 34.2% increased to
75.9% when the test was positive (O75th percentile) and
decreased to 18.0% when the test was negative (!25th
percentile). Application of the ESC-based cutoff levels
resulted in lower negative predicted values and very few
patients in the rule-in category.
The only diagnosis other than heart failure that was system-
atically assessed was chronic obstructive pulmonary disease
(COPD), defined as Global Initiative for COPD stage $2.
Fifty-four patients were diagnosed with COPD (20 in patients
with heart failure, 34 in patients without heart failure).
Discussion
BNP, whether it is measured with the NT-proBNP on
the Roche Elecsys, BNP on the Bayer Centaur, or BNP on
the Abbott Axsym, is a helpful diagnostic instrument in the
assessment of new slow-onset heart failure.When comparingthese 3 assays, the inference could be that most information
regarding the diagnosis of heart failure is given by
NT-proBNP, followed by BNP on the Centaur and least by
BNP on the Axsym, but differences were small. The
NT-proBNP showed marginally better discriminatory power
for detecting heart failure, as demonstrated by the c-statistic
of 0.86, the BNP on the Centaur and the Axsym scored 0.83
and 0.82, reespectively. There were no statistically signifi-
cant differences on the nonparametric c-statistic scale.
The c-statistic can be interpreted as the probability that
a test will rank a randomly chosen patient with heart failure
higher than a randomly chosen patient without heart fail-
ure6 (even if this situation would never emerge in practice).
However, the predictive values have more practical use,
because ultimately, a nonperfect diagnostic test should
provide an indication of presence of disease expressed as
a probability. Moreover we selected from our cohort only
patients with diagnostic uncertainty after taking history
taking and physical examination into account. Thus we
excluded patients with very high (O80%) or very low
(!10%) probability of heart failure, because these patients
do not need an additional diagnostic test. We used different
Table 3. Utility of 3 BNP assays for the Diagnosis of Heart Failure Applied in 111 Patients at intermediate risk of heart
failure and 34.2% prevalence
Patients with
Disease (n)
Patients without
Disease (n)
Prevalence of
Heart Failure
% of All
Patients
‘‘Percentile’’ guided
O75th percentile
NT-proBNP 24 8 75.0% 28.8%
Axsym-BNP 22 7 75.9% 26.1%
Centaur-BNP 23 9 71.9% 28.8%
!25th percentile
NT-proBNP 3 15 16.7% 16.2%
Axsym-BNP 6 15 19.7% 18.9%
Centaur-BNP 3 17 15.0% 18.0%
25the75th percentile
NT-proBNP 11 50 18.0% 55.0%
Axsym-BNP 10 51 16.4% 55.0%
Centaur-BNP 12 47 20.3% 53.2%
ESC guideline1
BNP O400 pg/mL (NT-proBNP O2,000 pg/mL)
NT-proBNP 0 0 na 0%
Axsym-BNP 3 0 100% 2.7%
Centaur-BNP 2 0 100% 1.8%
BNP !100 pg/mL (NT-proBNP !400 pg/mL)
NT-proBNP 30 73 29.1% 92.8%
Axsym-BNP 23 71 24.5% 84.7%
Centaur-BNP 23 73 24.0% 86.5%
BNP 100e400 pg/mL (NT-proBNP 400e2,000 pg/mL)
NT-proBNP 8 0 100% 7.2%
Axsym-BNP 12 2 85.7% 12.6%
Centaur-BNP 13 0 100% 11.7%
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failure, as proposed in the ESC guideline.1 The chosen cut-
off levels were the 75th and 25th percentiles, because no
evidence-based levels exist for patients suspected of new
slow-onset heart failure. For each test, the actual values
were 7 and 55 for NT-proBNP, 8 and 34 for BNP on the Ax-
sym, and 5 and 26 for BNP on the Centaur. In doing so we
created an intermediate group for whom no diagnosis could
be made, amounting to 55% of the patients, predominantly
owing to the choice of cutoff levels. Add to this amount the
false positives and false negatives, and the NT-proBNP,
BNP on Axsym, and BNP on Centaur have, respectively,
64.9% (n 5 72), 66.7% (n 5 74), and 68.0% (n 5 71) of
patients not adequately categorized. One could argue that
these figures are not very effective to reach a conclusion
in a fair number of patients, but fortunately a practicing
physician has more diagnostic tests at his or her disposal,
notably (among others) signs and symptoms, course in
time, ECG, and echocardiography.
The proposed cutoff levels from the ESC guideline ap-
pear to be too high, resulting in the majority of patients
ending up in the rule-out category, reducing the negative
predicted value.
Our results are in line with earlier reports. Recently, the
analytical performance and diagnostic accuracy of immu-
noassays for BNP, including the 3 assays we report, were
compared.5,8 The general conclusion was that all automated
BNP methods showed acceptable analytical performance
and clearly differentiated between healthy individuals and
heart failure patients. Because, however, results of one as-
say cannot be substituted for another, it is important toknow which specific assay is being used in a specific insti-
tution. As mentioned before, this ‘‘test research’’ is not di-
rectly applicable to daily practice.9 A study in patients with
selection criteria comparable to our study, ie, patients sus-
pected of new slow-onset heart failure, gave similar results
comparing a point-of-care BNP test with the NT-proBNP
assay.10 The utility of the tests was assessed by their ability
to prevent unnecessary referrals for echocardiography. The
point-of-care test prevented 24% and NT-proBNP 25% un-
necessary referrals with the use of the ‘‘single cutoff level’’
method. These results emphasize the ability of BNP to dis-
criminate between heart failure present versus heart failure
absent. The calibration, on the other hand, is not often re-
ported. Where calibration is not an issue in a ‘‘one cutoff
level’’ binary test, the interpretation in daily practice of a di-
agnostic test such as BNP would be ordinal by nature, eg,
a BNP level twice the upper level of normal would have
a different interpretation compared with a BNP level 10
times the upper level of normal. In the present study, all
3 BNP assays suffered from lack of calibration as single
tests. Figure 2 illustrates the lack of differentiation in the
lower 3 quintiles. It should be interesting to study whether
recalibration can be accomplished by adding other tests, no-
tably physical examination.
In the present study, consecutive patients were referred to
the participating hospitals from primary care to reduce se-
lection bias. Patients in need of urgent care were excluded;
consequently, our study does not address the diagnosis of
acute heart failure.
A point of interest is the absence of a ‘‘gold’’ standard
diagnostic test for heart failure. The presence of heart
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Fig. 2. Calibration of probability of heart failure by quintiles (Q)
of 3 BNP tests, with 95% confidence intervals.
734 Journal of Cardiac Failure Vol. 17 No. 9 September 2011failure in our study was established by consensus evaluation
using all available diagnostic information. This is an estab-
lished method as reference standard.11
In patients suspected of new slow-onset heart failure, 3
common BNP assays (Roche NT-proBNP, Abbott Axsym
BNP, and Bayer Centaur BNP) have similar and satisfactory
diagnostic power when used as single tests. However,
a valid diagnosis remains difficult in a substantial propor-
tion of patients and there is room for improvement in the
early diagnosis of heart failure in the absence of full echo-
cardiographic imaging.Disclosures
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